logo
Grey Anatomy star Eric Dane battles ALS: Why we must not ignore numbness in hands and legs

Grey Anatomy star Eric Dane battles ALS: Why we must not ignore numbness in hands and legs

Indian Express18-06-2025
Grey Anatomy star Eric Dane, who is much loved for embodying the character nicknamed 'Mc Dreamy,' has now revealed that he may have ignored first symptoms of ALS (amyotrophic lateral sclerosis), a progressive neuro-degenerative disease that affects nerve cells in the brain and spinal cord, making it harder for people to move, talk, eat and eventually breathe. He mistook a weakness in his right hand as a numbness from frequent texting.
'I had a 60-year-old patient who dismissed a weakness in his right palm and wrist as a routine nerve problem. Then he gradually lost functionality of his right arm, couldn't even swim and had quick muscle wasting. Early diagnosis helps us administer drugs to slow down the progression of this neuro-degenerative disease,' says Dr P N Renjen, senior consultant, neurology, Indraprastha Apollo Hospitals, Delhi.
'Sometimes symptoms overlap with other nerve conditions and could delay diagnosis. Therefore, one must consult a neurologist for any nerve complaint or whenever they feel a flickering in the muscles,' he advises.
What is ALS?
It's a type of progressive motor neuron disease that affects the nerves controlling muscle movement. Over time, the nerves that send signals from the brain to the muscles are damaged. This causes the muscles to become weak, and slowly, a person may lose the ability to move parts of their body. It often begins with small signs like weakness in a hand, leg, or arm, but it gradually worsens and can affect speaking, swallowing, and even breathing.
What causes ALS? Who is most vulnerable?
ALS usually affects people between the ages of 45 and 70, though it can happen earlier in cases of juvenile motor neuron disease. In most cases, there is no clear cause. Only a small percentage of people inherit it from a parent. The condition is rare and I see one, maybe two patients in a year. In India, it affects five in 100,000 people. ALS is mostly seen in men, very rarely in women.
What about diagnosis?
This is most important as we have to be very sure that the condition is not a side effect of other diseases. In those cases, a movement disorder is curable. ALS isn't. A nerve conduction test and electromyography (EMG) can help in diagnosis.
Can ALS be treated?
Unfortunately, there is no known cure yet. However, doctors can help manage the symptoms and slow down how quickly the disease progresses. Medicines like Riluzole and Edaravone can slow disease progression and extend survival. Physical therapy can help keep the muscles working for longer, and speech therapy becomes useful when talking or swallowing becomes difficult. As breathing muscles weaken, special equipment can help ease breathing. Wheelchairs, communication devices and feeding tubes can help maintain independence.
Emotional and psychological support is also important, both for the person with ALS and their loved ones. The journey may be tough but many people facing ALS show incredible strength and courage as they manage this condition.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Musk's Neuralink to test brain chips in clinical study in Great Britain
Musk's Neuralink to test brain chips in clinical study in Great Britain

Time of India

timean hour ago

  • Time of India

Musk's Neuralink to test brain chips in clinical study in Great Britain

Bengaluru: Elon Musk 's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts.

NTPC Simhadri strengthens critical care with ambulance
NTPC Simhadri strengthens critical care with ambulance

Time of India

timea day ago

  • Time of India

NTPC Simhadri strengthens critical care with ambulance

VISAKHAPATNAM: As part of its ongoing commitment to community welfare and healthcare development, NTPC Simhadri has provided an Advanced Life Support (ALS) ambulance to the Government Area Hospital in Narsipatnam of Anakapalli District. The fully equipped ambulance, valued at Rs35 lakh, was formally handed over on Wednesday. The inauguration ceremony was graced by Chintakayala Ayyanna Patrudu, Speaker of the Andhra Pradesh Legislative Assembly, along with Vijaya Krishnan, Collector and District Magistrate of Anakapalli District, and senior officials from NTPC Simhadri. Equipped with advanced medical and life-saving equipment, the ALS ambulance is designed to strengthen critical care transport services, especially for patients requiring immediate cardiac or respiratory interventions. This initiative will significantly enhance the hospital's capacity to deliver prompt and effective emergency care. Through impactful CSR efforts like these, NTPC Simhadri continues to play a vital role in improving healthcare infrastructure and supporting the well-being of communities in Narsipatnam and the surrounding rural areas.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store